JP2018503663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503663A5 JP2018503663A5 JP2017540230A JP2017540230A JP2018503663A5 JP 2018503663 A5 JP2018503663 A5 JP 2018503663A5 JP 2017540230 A JP2017540230 A JP 2017540230A JP 2017540230 A JP2017540230 A JP 2017540230A JP 2018503663 A5 JP2018503663 A5 JP 2018503663A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- hydrogen
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- -1 alkylphenyl ketone Chemical class 0.000 claims 2
- 125000006398 alkylpyrazinyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 0 **(CC1)CC(C(*2Cc3c(*)c(*)c(*)c(*)c3*)=O)=C1*1C2=*CC1 Chemical compound **(CC1)CC(C(*2Cc3c(*)c(*)c(*)c(*)c3*)=O)=C1*1C2=*CC1 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020195955A JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109737P | 2015-01-30 | 2015-01-30 | |
| US62/109,737 | 2015-01-30 | ||
| US201562148844P | 2015-04-17 | 2015-04-17 | |
| US62/148,844 | 2015-04-17 | ||
| US201562233757P | 2015-09-28 | 2015-09-28 | |
| US62/233,757 | 2015-09-28 | ||
| PCT/US2016/015817 WO2016123571A1 (en) | 2015-01-30 | 2016-01-29 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195955A Division JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503663A JP2018503663A (ja) | 2018-02-08 |
| JP2018503663A5 true JP2018503663A5 (enExample) | 2019-03-07 |
| JP6802172B2 JP6802172B2 (ja) | 2020-12-16 |
Family
ID=56544438
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540230A Active JP6802172B2 (ja) | 2015-01-30 | 2016-01-29 | ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2020195955A Active JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A Pending JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020195955A Active JP7579684B2 (ja) | 2015-01-30 | 2020-11-26 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
| JP2024122241A Pending JP2024160257A (ja) | 2015-01-30 | 2024-07-29 | ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9845324B2 (enExample) |
| EP (4) | EP3250208B1 (enExample) |
| JP (3) | JP6802172B2 (enExample) |
| KR (3) | KR20250134216A (enExample) |
| CN (2) | CN113149985B (enExample) |
| AU (4) | AU2016211243B2 (enExample) |
| BR (1) | BR112017016487B1 (enExample) |
| CA (3) | CA3209519A1 (enExample) |
| CY (1) | CY1123616T1 (enExample) |
| DK (2) | DK3250208T3 (enExample) |
| EA (1) | EA037552B1 (enExample) |
| ES (2) | ES3009132T3 (enExample) |
| FI (1) | FI3805222T3 (enExample) |
| HR (2) | HRP20201949T1 (enExample) |
| HU (2) | HUE052821T2 (enExample) |
| IL (5) | IL295286B2 (enExample) |
| LT (2) | LT3250208T (enExample) |
| MA (2) | MA55402B1 (enExample) |
| MD (2) | MD3805222T2 (enExample) |
| MX (3) | MX2021001096A (enExample) |
| PL (2) | PL3805222T3 (enExample) |
| PT (2) | PT3805222T (enExample) |
| RS (2) | RS61243B1 (enExample) |
| SG (2) | SG10201803508WA (enExample) |
| SI (2) | SI3805222T1 (enExample) |
| SM (2) | SMT202500087T1 (enExample) |
| WO (1) | WO2016123571A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295286B2 (en) | 2015-01-30 | 2024-10-01 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
| EP3408298B1 (en) * | 2016-01-29 | 2024-11-20 | Oncoceutics, Inc. | G protein-coupled receptor (gpcr) modulation by imipridones |
| AU2017228329B2 (en) | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018031987A1 (en) | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
| US10172862B2 (en) * | 2017-01-30 | 2019-01-08 | Oncoceutics, Inc. | Imipridones for gliomas |
| WO2018169994A1 (en) * | 2017-03-13 | 2018-09-20 | City Of Hope | m6A mRNA MODIFICATION IN CANCER TREATMENT |
| WO2019197024A1 (en) * | 2018-04-11 | 2019-10-17 | Chemestmed Ltd. | A method of modulating the rna methylation |
| TW202102251A (zh) | 2019-03-26 | 2021-01-16 | 日商富士軟片股份有限公司 | 抑制ｂ型肝炎病毒蛋白質產生的醫藥組成物、用以處理ｂ型肝炎的醫藥組成物及篩選方法 |
| IL294862A (en) * | 2020-01-29 | 2022-09-01 | Corcept Therapeutics Inc | Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (sgrms) and antibody checkpoint inhibitors |
| KR20230106583A (ko) * | 2020-08-06 | 2023-07-13 | 에오토보스 로란드 투도만예게템 | 신규한 이미프리돈 유도체의 합성 및 이들의 항암 활성에 대한 평가 |
| EP4223876A4 (en) | 2020-09-30 | 2025-12-10 | Fujifilm Corp | DOUBLE-STRANDED RNA THAT INHIBITS THE PRODUCTION OF A HEPATITIS B VIRUS PROTEIN, AND PHARMACEUTICAL COMPOSITION |
| CN116583276A (zh) * | 2020-11-13 | 2023-08-11 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| CN113100233B (zh) * | 2021-04-19 | 2022-02-08 | 中国农业科学院植物保护研究所 | 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用 |
| CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
| WO2024218275A1 (en) * | 2023-04-20 | 2024-10-24 | Institut Gustave Roussy | Liquid and solid compositions of imipridone derivatives |
| CN119306718A (zh) * | 2023-07-11 | 2025-01-14 | 中科中山药物创新研究院 | 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用 |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
| CN119198986B (zh) * | 2024-11-28 | 2025-03-11 | 淄博高新技术产业开发区生物医药研究院 | 化药中n-亚硝基双氯芬酸基因毒杂质含量的分析方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
| US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
| US7741285B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
| JP2005533748A (ja) | 2002-03-08 | 2005-11-10 | シグナル ファーマシューティカルズ，インコーポレイテッド | 増殖性障害および癌を治療、予防、または管理するための併用療法 |
| AU2003253186A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2004082570A2 (en) | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| AU2004258147B2 (en) | 2003-07-08 | 2009-04-30 | State Of Queensland Acting Through Queensland Health | Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| EP2350641B1 (en) | 2008-09-22 | 2014-09-24 | Amgen Inc. | A combination of a tnf alpha inhibitor, an iap inhibitor and a trail receptor agonist for use in treating cancer |
| AU2009324464B2 (en) | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
| US8895581B2 (en) | 2010-05-17 | 2014-11-25 | Boehringer Ingelheim International Gmbh | 1H-imidazo[4,5-c]quinolines |
| US8735386B2 (en) | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
| US20140287931A1 (en) * | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| US20130102595A1 (en) * | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| PT3679934T (pt) * | 2011-04-29 | 2024-09-05 | Penn State Res Found | Indução do gene trail de pequenas moléculas por células normais e tumorais enquanto terapia anticancro |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
| BR112015023256A2 (pt) * | 2013-03-13 | 2017-07-18 | Oncoceutics Inc | terapia de combinação com 7-benzil-10-(2-metil-benzil)-2,6,7,8,9,10-hexaidroimidazol[1,2-a]pirido[4,3-d]pirimidin-5(3h)-ona. |
| US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| CN106163524B (zh) * | 2013-11-15 | 2019-11-08 | 昂克希尔迪克斯有限公司 | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法 |
| SMT202400497T1 (it) * | 2014-03-31 | 2025-01-14 | Scripps Research Inst | Farmacoforo per induzione di trail |
| KR20150114239A (ko) * | 2014-04-01 | 2015-10-12 | 제일모직주식회사 | 내열성 및 착색성이 향상된 열가소성 수지 조성물 |
| IL295286B2 (en) * | 2015-01-30 | 2024-10-01 | Oncoceutics Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy |
| CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
-
2016
- 2016-01-29 IL IL295286A patent/IL295286B2/en unknown
- 2016-01-29 MX MX2021001096A patent/MX2021001096A/es unknown
- 2016-01-29 SI SI201631886T patent/SI3805222T1/sl unknown
- 2016-01-29 PT PT201980620T patent/PT3805222T/pt unknown
- 2016-01-29 MD MDE20220113T patent/MD3805222T2/ro unknown
- 2016-01-29 EP EP16744237.5A patent/EP3250208B1/en active Active
- 2016-01-29 ES ES20198062T patent/ES3009132T3/es active Active
- 2016-01-29 PT PT167442375T patent/PT3250208T/pt unknown
- 2016-01-29 PL PL20198062.0T patent/PL3805222T3/pl unknown
- 2016-01-29 SM SM20250087T patent/SMT202500087T1/it unknown
- 2016-01-29 EP EP25152627.3A patent/EP4516359A3/en active Pending
- 2016-01-29 SM SM20200696T patent/SMT202000696T1/it unknown
- 2016-01-29 LT LTEP16744237.5T patent/LT3250208T/lt unknown
- 2016-01-29 MA MA55402A patent/MA55402B1/fr unknown
- 2016-01-29 EP EP24210662.3A patent/EP4512483A3/en active Pending
- 2016-01-29 CN CN202110266214.3A patent/CN113149985B/zh active Active
- 2016-01-29 CA CA3209519A patent/CA3209519A1/en active Pending
- 2016-01-29 AU AU2016211243A patent/AU2016211243B2/en active Active
- 2016-01-29 HR HRP20201949TT patent/HRP20201949T1/hr unknown
- 2016-01-29 DK DK16744237.5T patent/DK3250208T3/da active
- 2016-01-29 EA EA201791727A patent/EA037552B1/ru unknown
- 2016-01-29 MD MDE20170317T patent/MD3250208T2/ro unknown
- 2016-01-29 MA MA41434A patent/MA41434B1/fr unknown
- 2016-01-29 KR KR1020257029332A patent/KR20250134216A/ko active Pending
- 2016-01-29 EP EP20198062.0A patent/EP3805222B1/en active Active
- 2016-01-29 HU HUE16744237A patent/HUE052821T2/hu unknown
- 2016-01-29 DK DK20198062.0T patent/DK3805222T3/da active
- 2016-01-29 MX MX2017009841A patent/MX379425B/es unknown
- 2016-01-29 JP JP2017540230A patent/JP6802172B2/ja active Active
- 2016-01-29 IL IL288525A patent/IL288525B/en unknown
- 2016-01-29 PL PL16744237T patent/PL3250208T3/pl unknown
- 2016-01-29 SG SG10201803508WA patent/SG10201803508WA/en unknown
- 2016-01-29 RS RS20201566A patent/RS61243B1/sr unknown
- 2016-01-29 LT LTEP20198062.0T patent/LT3805222T/lt unknown
- 2016-01-29 KR KR1020177022405A patent/KR102618971B1/ko active Active
- 2016-01-29 HU HUE20198062A patent/HUE070309T2/hu unknown
- 2016-01-29 SG SG11201706062TA patent/SG11201706062TA/en unknown
- 2016-01-29 IL IL312936A patent/IL312936A/en unknown
- 2016-01-29 CA CA3209515A patent/CA3209515A1/en active Pending
- 2016-01-29 RS RS20250206A patent/RS66551B1/sr unknown
- 2016-01-29 HR HRP20250250TT patent/HRP20250250T1/hr unknown
- 2016-01-29 ES ES16744237T patent/ES2839401T3/es active Active
- 2016-01-29 SI SI201631003T patent/SI3250208T1/sl unknown
- 2016-01-29 BR BR112017016487-6A patent/BR112017016487B1/pt active IP Right Grant
- 2016-01-29 WO PCT/US2016/015817 patent/WO2016123571A1/en not_active Ceased
- 2016-01-29 CA CA2975476A patent/CA2975476C/en active Active
- 2016-01-29 FI FIEP20198062.0T patent/FI3805222T3/fi active
- 2016-01-29 CN CN201680008476.7A patent/CN107427516B8/zh active Active
- 2016-01-29 KR KR1020237044537A patent/KR102856422B1/ko active Active
- 2016-02-22 US US15/049,613 patent/US9845324B2/en active Active
-
2017
- 2017-07-27 IL IL253689A patent/IL253689B/en active IP Right Grant
- 2017-07-28 MX MX2023000782A patent/MX2023000782A/es unknown
- 2017-11-20 US US15/817,896 patent/US10266533B2/en active Active
-
2019
- 2019-02-27 US US16/287,195 patent/US20190194201A1/en not_active Abandoned
-
2020
- 2020-04-22 IL IL274135A patent/IL274135B/en unknown
- 2020-11-26 JP JP2020195955A patent/JP7579684B2/ja active Active
- 2020-12-07 AU AU2020286168A patent/AU2020286168B8/en active Active
- 2020-12-07 CY CY20201101158T patent/CY1123616T1/el unknown
-
2021
- 2021-06-24 US US17/357,008 patent/US11976068B2/en active Active
-
2022
- 2022-09-06 AU AU2022228096A patent/AU2022228096A1/en not_active Abandoned
-
2024
- 2024-03-12 US US18/603,075 patent/US20240270746A1/en active Pending
- 2024-05-22 AU AU2024203421A patent/AU2024203421A1/en active Pending
- 2024-07-29 JP JP2024122241A patent/JP2024160257A/ja active Pending
- 2024-12-12 US US18/979,567 patent/US20250109133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503663A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| CN115667238A (zh) | 一种五并五元环衍生物及其在医药上的应用 | |
| RU2016134751A (ru) | Соединения | |
| JP2015520140A5 (enExample) | ||
| JP2016501882A5 (enExample) | ||
| JP2015518903A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| JP2017519781A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2015529217A5 (enExample) | ||
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2019516739A5 (enExample) | ||
| JP2018504441A5 (enExample) |